We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

10 Top Penny Stocks To Watch This Week With Potential Biotech Catalysts

4 56 21
26.09.2021

Last week we talked about biotech penny stocks with upcoming catalysts. That article received a lot of attention and for obvious reasons. As I explained, few industries will host companies that will tell you when they’ve got news coming. Biotech is one of these industries, and it makes for exciting market conditions. You’ve got the “buy the rumor, sell the news” trend to navigate.

Then there’s the market surprise where companies deliver results far surpassing what Wall Street initially thought. Something to remember is that there are so many different steps involved in taking a biotech company from pre-clinical to commercial stages. Each phase presents a milestone opportunity.

Biotech stocks are exciting to watch, especially around these potential milestone events. These are all things to keep in mind, whether it’s an industry presentation, new study data, or something else.

We’ve got several things to keep in mind in the stock market this week. It’s the final week of September, which means an end to one of the most challenging months in the stock market for 2021. It’s also the end of the 3rd quarter. Over the last 12 months, companies have reported exact dates and broad periods.

“By the end of Q3” is one of these broad timeframes. So today, we’re going to look at 10 top penny stocks presumed to have something to take notice of this week. Will these events become bullish or bearish catalysts? If you’re searching for penny stocks to buy, I’ll leave that final decision up to you. At the very least, you’re armed with information heading into the end of September and the end of Q3.

Zynerba is one of the company’s we discussed last week on a list of penny stocks analysts say to buy right now. H.C. Wainwright analyst Oren Livnat reiterated the firm’s Buy rating on ZYNE stock and a price target of $9. Other than that, there are other more scientific things to consider when looking at Zynerba. The company specializes in transdermal therapies for rare and near-rare disorders.

Read more: Best Penny Stocks to Buy Right Now? 3 to Watch in October

It made several presentations this month on its ZYN002 platform, trademarked as Zygel. This product is a transdermal gel administered to children with developmental and epileptic encephalopathy. Recent results of ongoing studies have demonstrated how Zygel can benefit patients even during longer-term time frames. Patients with Autism Spectrum Disorder who completed a 38-week treatment showed “statistically significant improvements” compared to baselines in the study.

As you’ll come to find, the Cantor Global Healthcare Conference will be a point of focus for many companies this week. The conference goes from September 27 – September 30. On September 27th, Zynerba’s CEO Armando Anido begins his presentation at 11:20 AM ET. Keep this in mind if ZYNE is on your list of penny stocks this week.

Another one of the companies that we’ve frequently discussed this month is Verastem. Not only was it highlighted for bullish analyst sentiment, but it was also spotlighted for a biotech event last week. Verastem announced that study data in a combination of its VS-6766 and defactinib demonstrated potential in treating ovarian cancer. The company said that the median progression-free survival across all patients was 23 months.

In addition to these results, Verastem also announced a clinical collaboration agreement with Amgen (NASDAQ:AMGN), evaluating a combination of VS-6766 with Amgen’s sotorasib, trademarked as LUMAKRAS, in patients with non-small cell lung cancer. This trial is expected to begin by the end of the year. So that could be something to keep........

© Entrepreneur


Get it on Google Play